Roila F, Tonato M, Basurto C, Minotti V, Ballatori E, del Favero A
Divisione di Oncologia Medica, Ospedale Policlinico, Perugia, Italy.
Eur J Cancer Clin Oncol. 1987 Jun;23(6):615-7. doi: 10.1016/0277-5379(87)90255-0.
Sixty-two patients treated for the first time with i.v. CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting. Complete protection from vomiting/nausea was obtained in 85%/80% in the group treated with MP; in 60%/65% in the group treated with MTC and in 38%/42% in the group treated with DMP. Average number of vomiting episodes was 2.4 with MP, and 1.7 with MTC and 6.2 with DMP. Older patients seem to be a prognostically unfavorable subgroup. Side-effects were mild and infrequent. We conclude that MP and MTC are probably equally efficacious antiemetic treatments in patients undergoing i.v. CMF chemotherapy, but due to the risk of extrapyramidal reactions with MTC, MP probably should be the treatment of choice in these patients.
62例首次接受静脉注射CMF治疗的患者被纳入一项双盲对照研究，旨在评估3种不同药物（甲基强的松龙（MP）、甲氧氯普胺（MTC）和多潘立酮（DMP））预防化疗引起的恶心和呕吐的疗效。MP治疗组中85%/80%的患者完全避免了呕吐/恶心；MTC治疗组为60%/65%，DMP治疗组为38%/42%。MP治疗组呕吐发作的平均次数为2.4次，MTC治疗组为1.7次，DMP治疗组为6.2次。老年患者似乎是预后不良的亚组。副作用轻微且不常见。我们得出结论，在接受静脉注射CMF化疗的患者中，MP和MTC可能是同样有效的止吐治疗方法，但由于MTC有发生锥体外系反应的风险，MP可能应该是这些患者的首选治疗方法。
